Ronchi A.a· Montella M.a· Carraturo E.a· Clery E.a· Zito Marino F.a· Amato M.a· Argenziano G.b· Moscarella E.b· Brancaccio G.b· Troiani T.c· Alfano P.a· Alfano R.d· Franco R.a· Cozzolino I.a

Author affiliations

aPathology Unit, Department of Mental and Physical Health and Preventive Medicine, University of Campania “Luigi Vanvitelli”, Naples, Italy
bDermatology Unit, Department of Mental and Physical Health and Preventive Medicine, Università Degli Studi Della Campania “Luigi Vanvitelli”, Naples, Italy
cOncology Unit, Department of Precision Medicine, Università Della Campania “Luigi Vanvitelli”, Naples, Italy
dDepartment of Anesthesiology, Surgery and Emergency, University of Campania “Luigi Vanvitelli”, Naples, Italy

Log in to MyKarger to check if you already have access to this content.

Buy FullText & PDF Unlimited re-access via MyKarger Unrestricted printing, no saving restrictions for personal use read more

CHF 38.00 *
EUR 35.00 *
USD 39.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!

If you would like to redeem your KAB credit, please log in.

Save over 20% compared to the individual article price.

Learn more

Rent via DeepDyve Unlimited fulltext viewing of this article Organize, annotate and mark up articles Printing and downloading restrictions apply

Start free trial

Subscribe Access to all articles of the subscribed year(s) guaranteed for 5 years Unlimited re-access via Subscriber Login or MyKarger Unrestricted printing, no saving restrictions for personal use read more

Subcription rates

Select

* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details

First-Page Preview

Received: January 23, 2023
Accepted: February 15, 2023
Published online: February 20, 2023

Number of Print Pages: 8
Number of Figures: 3
Number of Tables: 2

ISSN: 0001-5547 (Print)
eISSN: 1938-2650 (Online)

For additional information: https://www.karger.com/ACY

Abstract

Introduction: Cytological samples from cutaneous melanoma (CM) metastases may be the only biomaterial available for diagnostic and predictive purpose in the clinical practice. BRAF evaluation from cytological samples actually implies the loss of one or more diagnostic smears, or the execution of one or more passes to obtain dedicated cytological samples. We tested BRAF molecular evaluation in CM metastases on cell suspension obtained from fine needle aspiration cytology (FNAC) needle rinses. Methods: Forty-two patients with lymph node enlargements and a previous CM were enrolled. Patients were submitted to FNAC, and direct smears and cell-block were prepared for diagnostic purpose. The needle was carefully flushed in a vial containing 350 μL of nuclease-free water and a cell suspension was obtained for BRAF molecular evaluation. Molecular evaluation was also performed on histological samples for statistics. Results: The series included 35 CM metastases and 7 reactive lymphadenopathies. Three cases resulted inadequate and adequacy was 92.9%. BRAF V600E/Ec mutations were found in 7 out of 32 (21.9%) CM metastases cases. BRAF mutations other than V600E/Ec were found in 2 out of 32 (6.25%) cases. Sensitivity, specificity, positive predictive value, and negative predictive value resulted 100%. Conclusion: BRAF molecular evaluation in CM metastases on cell suspension obtained from FNAC needle rinses is a time-sparing and accurate technique allowing to spare biomaterial in the clinical setting.

© 2023 S. Karger AG, Basel

References Reed KB, Brewer JD, Lohse CM, Bringe KE, Pruitt CN, Gibson LE. Increasing incidence of MM among young adults: an epidemiological study in Olmsted County, Minnesota. Mayo Clin Proc. 2012;87:328–34. Switzer B, Puzanov I, Skitzki JJ, Hamad L, Ernstoff MS. Managing metastatic melanoma in 2022: a clinical review. JCO Oncol Pract. 2022 May;18(5):335–51. Brand CU, Ellwanger U, Stroebel W, Meier F, Schlagenhauff B, Rassner G, et al. Prolonged survival of 2 years or longer for patients with disseminated melanoma. An analysis of related prognostic factors. Cancer. 1997 Jun 15;79(12):2345–53. Dummer R, Hauschild A, Lindenblatt N, Pentheroudakis G, Keilholz U, ESMO Guidelines Committee. Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015 Sep;26(Suppl 5):v126–32. Kunz M, Vera J. Modelling of protein kinase signaling pathways in melanoma and other cancers. Cancers. 2019;11(4):465. Greaves WO, Verma S, Patel KP, Davies MA, Barkoh BA, Galbincea JM, et al. Frequency and spectrum of BRAF mutations in a retrospective, single-institution study of 1112 cases of melanoma. J Mol Diagn. 2013;15(2):220–6. Rubinstein JC, Sznol M, Pavlick AC, Ariyan S, Cheng E, Bacchiocchi A, et al. Incidence of the V600K mutation among melanoma patients with BRAF mutations, and potential therapeutic response to the specific BRAF inhibitor PLX4032. J Transl Med. 2010 Jul 14;8(1):67. National Comprehensive Cancer Network (NCCN). [cited 2023 Jan 4]. Available from: http://www.nccn.org/index.asp. Valachis A, Ullenhag GJ. Discrepancy in BRAF status among patients with metastatic malignant melanoma: a meta-analysis. Eur J Cancer. 2017;81:106–15. Michielin O, van Akkooi ACJ, Ascierto PA, Dummer R, Keilholz U, ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†. Ann Oncol. 2019;30(12):1884–901. Ronchi A, Montella M, Zito Marino F, Argenziano G, Moscarella E, Brancaccio G, et al. Cytologic diagnosis of metastatic melanoma by FNA: a practical review. Cancer Cytopathol. 2022 Jan;130(1):18–29. Ronchi A, Zito Marino F, Toni G, Pagliuca F, Russo D, Signoriello G, et al. Diagnostic performance of melanocytic markers for immunocytochemical evaluation of lymph-node melanoma metastases on cytological samples. J Clin Pathol. 2022 Jan;75(1):45–9. Ronchi A, Zito Marino F, Moscarella E, Brancaccio G, Argenziano G, Troiani T, et al. PRAME immunocytochemistry for the diagnosis of melanoma metastases in cytological samples. Diagnostics. 2022 Mar 6;12(3):646. Ronchi A, Montella M, Zito Marino F, Caraglia M, Grimaldi A, Argenziano G, et al. Predictive evaluation on cytological sample of metastatic melanoma: the role of BRAF immunocytochemistry in the molecular era. Diagnostics. 2021 Jun 18;11(6):1110. Da Cunha Santos G, Saieg MA. Preanalytic specimen triage: smears, cell blocks, cytospin preparations, transport media, and cytobanking. Cancer Cytopathol. 2017;125(S6):455–64. Barroca H, Bode-Lesniewska B, Cozzolino I, Zeppa P. Management of cytologic material, preanalytic procedures and biobanking in lymph node cytopathology. Cytopathology. 2019 Jan;30(1):17–30. Lombardi A, Russo M, Luce A, Morgillo F, Tirino V, Misso G, et al. Comparative study of NGS platform Ion Torrent personal genome machine and Therascreen Rotor-Gene Q for the detection of somatic variants in cancer. High Throughput. 2020;9(1):4. Cancer.net. the American Society of Clinical Oncology (ASCO). [cited 2023 Jan 4]. Available from: https://www.cancer.net/cancer-types/melanoma/statistics. Ronchi A, Pagliuca F, Zito Marino F, Argenziano G, Brancaccio G, Alfano R, et al. Second Diagnostic Opinion by Experienced Dermatopathologists in the setting of a referral regional melanoma unit significantly improves the clinical management of patients with cutaneous melanoma. Front Med. 2020;7:568946. Roy-Chowdhuri S. Molecular testing of residual cytology samples: rethink, reclaim, repurpose. Cancer Cytopathol. 2019 Feb;127(1):15–7. Article / Publication Details

First-Page Preview

Received: January 23, 2023
Accepted: February 15, 2023
Published online: February 20, 2023

Number of Print Pages: 8
Number of Figures: 3
Number of Tables: 2

ISSN: 0001-5547 (Print)
eISSN: 1938-2650 (Online)

For additional information: https://www.karger.com/ACY

Copyright / Drug Dosage / Disclaimer Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.